Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 25.25 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2026-06-30 was 4.67K shares.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2026-03-31 was 20.58K shares, a 1272.27% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2025-09-30 was 1.33K shares.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2025 was 2.83K shares, a 93.72% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2024 was 45.11K shares, a 2901.13% increase from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2023 was 1.50K shares, a 93.18% decline from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2022 was 22.02K shares, a 3362.89% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 4.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 25.25K shares 10-Q · filed 2026-08-06 | 25.25K shares derived: sum of 3 quarters · filed 2026-08-06 | 26.59K shares derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | 20.58K shares 10-Q · filed 2026-05-12 | 20.58K shares derived: sum of 2 quarters · filed 2026-05-12 | 21.92K shares derived: sum of 3 quarters · filed 2026-05-12 | 21.92K shares derived: sum of 4 quarters · filed 2026-05-12 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 1.33K shares derived: sum of 2 quarters · filed 2026-03-09 | 1.33K shares derived: sum of 3 quarters · filed 2026-03-09 | 2.83K shares 10-K · filed 2026-03-09 | |
| 2025-09-30 | 1.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.33K shares derived: sum of 2 quarters · filed 2025-11-12 | 2.83K shares 10-Q · filed 2025-11-12 | 29.26K shares derived: sum of 4 quarters · filed 2025-11-12 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 1.50K shares 10-Q · filed 2025-08-05 | 27.93K shares derived: sum of 3 quarters · filed 2025-08-05 | 27.93K shares derived: sum of 4 quarters · filed 2025-08-05 | |
| 2025-03-31 | 1.50K shares 10-Q · filed 2025-05-06 | 27.93K shares derived: sum of 2 quarters · filed 2025-05-06 | 27.93K shares derived: sum of 3 quarters · filed 2025-05-06 | 37.64K shares derived: sum of 4 quarters · filed 2025-05-06 | |
| 2024-12-31 | 26.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 26.43K shares derived: sum of 2 quarters · filed 2025-03-11 | 36.14K shares derived: sum of 3 quarters · filed 2025-03-11 | 45.11K shares 10-K · filed 2025-03-11 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 9.71K shares derived: sum of 2 quarters · filed 2024-11-07 | 18.68K shares 10-Q · filed 2024-11-07 | 19.68K shares derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | 9.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 18.68K shares 10-Q · filed 2024-08-06 | 19.68K shares derived: sum of 3 quarters · filed 2024-08-06 | -23.66K shares derived: sum of 4 quarters · filed 2024-08-06 | |
| 2024-03-31 | 8.97K shares 10-Q · filed 2024-05-07 | 9.97K shares derived: sum of 2 quarters · filed 2024-05-07 | -33.37K shares derived: sum of 3 quarters · filed 2024-05-07 | ||
| 2023-12-31 | 1.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -42.33K shares derived: sum of 2 quarters · filed 2024-03-12 | 1.50K shares 10-K · filed 2024-03-12 | ||
| 2023-09-30 | -43.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 503.00 shares 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | 43.84K shares 10-Q · filed 2023-08-08 | ||||
| 2022-12-31 | -283.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -255.90K shares derived: sum of 2 quarters · filed 2024-03-12 | -255.90K shares derived: sum of 3 quarters · filed 2024-03-12 | 22.02K shares 10-K · filed 2024-03-12 | |
| 2022-09-30 | 27.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 27.51K shares derived: sum of 2 quarters · filed 2022-11-08 | 305.43K shares 10-Q · filed 2022-11-08 | 302.30K shares derived: sum of 4 quarters · filed 2023-03-07 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 277.93K shares 10-Q · filed 2022-08-09 | 274.79K shares derived: sum of 3 quarters · filed 2023-03-07 | ||
| 2022-03-31 | 277.93K shares 10-Q · filed 2022-05-10 | 274.79K shares derived: sum of 2 quarters · filed 2023-03-07 | |||
| 2021-12-31 | -3.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | 636.00 shares 10-K · filed 2023-03-07 | 19.09K shares 10-K · filed 2022-03-08 | ||
| 2021-09-30 | 3.77K shares 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |